Mimedx (MDXG) Other financing activities (2011 - 2024)
Mimedx (MDXG) posted Other financing activities of $2000.0 for Q4 2024, down 99.48% sequentially from $388000.0 in Q3 2024, and down 99.66% YoY from $594000.0 in Q1 2024.
Mimedx (MDXG) Other financing activities (2011 - 2024) Analysis & Trends
Mimedx has reported Other financing activities for 14 years, with the latest figure at $2000.0 in Q4 2024.
- Quarterly Other financing activities fell 99.66% year-over-year to $2000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $2000.0 (down 99.9% YoY) and the FY2024 annual result came in at $1.4 million, up 40.0% from the prior year.
- Other financing activities fell to $2000.0 in Q4 2024 per MDXG's latest filing, from $388000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $915000.0 in Q1 2021 and troughed at $2000.0 in Q4 2024.
- A 5-year average of $274888.9 and a median of $205000.0 in 2022 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 1120.0% in 2024, down 99.66% in 2024.
- Over 5 years, Other financing activities stood at $41000.0 in 2020, then fell by 19.51% to $33000.0 in 2021, then surged by 281.82% to $126000.0 in 2022, then surged by 371.43% to $594000.0 in 2023, then plunged by 99.66% to $2000.0 in 2024.
- According to Business Quant data, Other financing activities over the past three periods registered $2000.0, $388000.0, and $244000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 388,000.00 |
| Sep 30, 2024 | 388,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Mar 31, 2024 | 766,000.00 |
| Mar 31, 2024 | 766,000.00 |
| Dec 31, 2023 | 594,000.00 |
| Dec 31, 2023 | 594,000.00 |
| Sep 30, 2023 | 386,000.00 |
| Sep 30, 2023 | 386,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Dec 31, 2022 | 126,000.00 |
| Dec 31, 2022 | 126,000.00 |
| Sep 30, 2022 | 137,000.00 |
| Sep 30, 2022 | 137,000.00 |
| Jun 30, 2022 | 271,000.00 |
| Jun 30, 2022 | 271,000.00 |